Canada authorises first plant-based COVID-19 vaccine

Medicago's two-dose vaccine can be given to adults aged 18 to 64, but there is insufficient data on the shots in elderly people above 65 years.

Canadian regulators said Thursday Medicago's two-dose vaccine can be given to adults ages 18 to 64, but said there's too little data on the shots in people 65 and older.

The decision was based on a study of 24,000 adults that found the vaccine was 71% effective at preventing COVID-19 — although that was before the omicron variant emerged. Side effects were mild, including fever and fatigue.

Medicago uses plants as living factories to grow virus-like particles, which mimic the spike protein that coats the coronavirus. The particles are removed from the plants' leaves and purified. Another ingredient, an immune-boosting chemical called an adjuvant that is made by British partner GlaxoSmithKline, is added to the shots.

While numerous COVID-19 vaccines have been rolled out around the world, global health authorities are looking to additional candidates in hopes of increasing the worldwide supply.

Quebec City-based Medicago is developing plant-based vaccines against multiple other diseases, and the COVID-19 vaccine may help spur more interest in this new method of medical manufacturing.

ALSO READ | Very small blood clot risk after first AstraZeneca Covid shot, say UK studies

ALSO READ | Over 20 million Covid-19 vaccine doses administered in Mumbai